Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanxinning is a Traditional Chinese Medicine (TCM) formulation primarily composed of extracts from *Salvia miltiorrhiza* (Danshen) and *Ligusticum chuanxiong* (Chuanxiong). It is widely used in China for the treatment of cardiovascular diseases, including coronary heart disease, angina pectoris, and coronary arterial microvascular disease. The drug works by promoting blood circulation, resolving blood stasis, and dilating coronary arteries, which improves myocardial blood supply and protects against ischemia-reperfusion injury. It is available in various forms, including tablets and injections, and is frequently evaluated in post-marketing clinical trials to confirm its efficacy in specific patient populations, such as those undergoing percutaneous coronary intervention (PCI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guanxinning.